Physician profile
John G Brady
NPI 1154382513
$1,692.32
in general payments reported to CMS, 2019-2025
22 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $100 · 2021: $528 · 2022: $256 · 2023: $44.19 · 2024: $520 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410 · Travel and Lodging: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.36 |
| Travel and Lodging | $397.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $446.19 | 2024-2025 | Iovera |
| Abbvie INC. | $252.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.89 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $130.73 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.86 | 2021-2025 | Xifaxan |
| Amgen INC. | $97.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $79.39 | 2020-2023 | Farxiga |
| Lilly USA, LLC | $71.57 | 2021-2023 | Emgality, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.36 | 2025 | Caplyta |
| Radius Health, INC. | $43.64 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $42.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.42 | 2021 | |
| Phathom Pharmaceuticals, INC. | $26.11 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $22.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.19 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.66 | 2021 | |
| Horizon Therapeutics Plc | $15.76 | 2023 | Krystexxa |
| Sunovion Pharmaceuticals INC. | $14.72 | 2020 | |
| Ironshore Pharmaceuticals INC. | $14.65 | 2021 | |
| Lundbeck LLC | $13.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.